At Lifebit, we're pushing forward the frontiers of health and knowledge by democratizing access to omics data.

To cure diseases you need data. Lifebit, is a London-based developer of a genomics and bioinformatics platform, making waves in the world of scientific research with a mission to democratize access to omics data, through its innovative platform, designed to do just that. With a focus on making genomics analysis reproducible and easy to share, Lifebit is simplifying the process for researchers across all levels of expertise, generating insights fast and accelerating the pace of scientific discovery.

Lifebit's one-click solution for genomics analysis empowers researchers with access to the widest range of tools and resources. In addition to its powerful analysis capabilities, Lifebit's platform also includes visualization tools for large data sets associated with human genome sequencing. This makes it possible for researchers to run complex analyses and generate meaningful insights that can be used to advance our understanding of genetics and disease.

The company is a graduate of TechStars accelerator and works with top-tier pharmaceutical organizations, global research institutes, genetics companies, and other institutions globally, including the likes of Genomics England and Boehringer Ingelheim. In 2021 the company secured funding of $60 million, from a top-tier fund, Tiger Global.

In February of 2023, Lifebit announced its part in the BeginNGS project, a genome sequencing program supported by Greece’s National Organization of Public Health. The initiative will enable the sequencing of genomes of 1,000 newborns in its first year for the early detection of rare diseases, aiming to expand the sequencing to all newborns in Greece until 2027.